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Case ReportsAortic root thrombosis after transhiatal esophagectomy: A case
reportTomasz A. Timek, MD,a Craig T. Alguire, MD,a Kevin G. Wolschleger, MD,a and Mathew H. Chung, MD,b
Grand Rapids, MichAscending aortic thrombosis is a rare clinical entity with
potential lethal consequences, yet forms of therapy are
not uniform. We present the clinical course of a patient
who developed aortic root thrombus after transhiatal esoph-
agectomy for an esophageal malignancy.CLINICAL SUMMARY
A 52-year-old man with history of tobacco abuse and
esophageal adenocarcinoma initially treated with neoad-
juvant chemoradiation presented to our emergency de-
partment with left hand weakness and ataxia 3 weeks
after transhiatal resection of the esophagus. The patient’s
symptoms resolved in the emergency department, he re-
ceived 325 mg aspirin, and initial computed tomography
(CT) scan of the patient’s head did not reveal abnormal-
ities, neither did a carotid duplex ultrasound test. Mag-
netic resonance imaging (MRI) scans, however,FIGURE 1. A, Computed tomography scan of the patient’s chest on initial adm
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tery distribution consistent with the patient’s symptoms.
Workup of potential embolic sources included a transtho-
racic echo, which revealed an echogenic density in the
noncoronary sinus of the aortic root suggestive of throm-
bus. The aortic valve was trileaflet and without stenosis
or regurgitation. CT angiogram of the chest confirmed
aortic root thrombus (Figure 1) and evidence of embolus
in the left hepatic artery as well as splenic infarcts. The
thoracic aorta appeared normal sized without evidence of
calcifications or ulcerations. These findings were not
present on preoperative imaging before the esophagec-
tomy. Immediate anticoagulation therapy was started
with heparin and follow-up MRI scan after 4 days
(Figure 2) showed the thrombus to be stable and approx-
imately 37 3 28 3 16 mm in size. No other aortic pa-
thology was noted. The patient remained asymptomatic
and surgical extraction of the thrombus was considered,
but he was unwilling to proceed in light of the recent
esophagectomy. Hypercoagulable workup was intiated
and the patient was subsequently transitioned to warfarin
and discharged to home on hospital day 5. One week af-
ter discharge, the patient represented to the emergency
department with acute right lower extremity pain and
numbness distal to the knee with a cool extremity and
no palpable distal pulses. International normalized ratio
was therapeutic at 3.6. CT angiogram revealed the aortic
root thrombus to be no longer present (Figure 3) withission demonstrating extensive aortic root thrombus on axial views of the
dmission demonstrating extensive aortic root thrombus on saggital views of
bus.
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FIGURE 2. Sagittal magnetic resonance imaging view of the entire
thoracic aorta 4 days after the patient’s admission to the hospital,
showing stable size of aortic root thrombus following initiation of anti-
coagulation therapy and no other abnormalities within the thoracic
aorta.
FIGURE 3. Computed tomography scan of the patient’s chest on read-
mission to the hospital for acute lower extremity ischemia. Axial im-
age shows resolution of aortic root thrombus with normal root
morphology.
Case Reportsmultiple new emboli in the abdomen, pelvis, and lower
extremities, including the right common and superficial
femoral arteries. The patient underwent emergent femo-
ral thromboembolectomy, recovered uneventfully, and
continues to receive anticoagulant therapy. Genetic and
hematologic testing for hypercoagulable state was
unrevealing.
DISCUSSION
Ascending aortic thrombus has been reported in the lit-
erature in patients with malignancies, particularly after
cisplatin-based chemotherapy.1,2 Root thrombosis has
been described to result in myocardial infarction3 or inter-
mittent ischemia.4 The clinical treatment of this poten-
tially fatal entity has not been uniformly defined, with
both conservative1,2 and surgical5,6 management being
advocated. We describe a patient with multiple risk
factors for hypercoagulability who developed the
unusual complication of aortic root thrombosis after
transhiatal esophagectomy. Recent surgery, history of
malignancy, chemotherapy, and tobacco use are clear
identifiable risk factors, yet the mechanical effect of
transhiatal approach on the geometry of the aortic root
must also be considered. It is feasible that local factors
and a hypercoagulable milieu contributed to the
formation of thrombus in an area of high flow. To our
knowledge, this is the first case in the literature ofThe Journal of Thoracic and Caaortic root thrombosis after esophageal resection. Based
on this anecdotal experience and a published small
single-center series,7 we advocate early surgical interven-
tion in selected patients because therapeutic anticoagula-
tion does not appear to be protective. The aortic root is
a dynamic structure with torsional deformation,8 and
therefore even if no local effect on coronary perfusion
is present, the risk of embolization can be presumed to
be significant.
This is exemplified by our patient, who upon return to
the hospital had evidence of diffuse embolization while re-
ceiving therapeutic anticoagulation medication. Although
successful conservative therapy with anticoagulation
agents has been described in patients with ascending aortic
thrombosis, those patients were poor surgical candidates
with metastatic lung malignancies. On the other hand, ex-
traction of aortic thrombus appears to have low mortality
and effectively prevents recurrent embolization.7 As
such, appropriate surgical candidates who develop aortic
root thrombus should be offered intervention early to pre-
vent possible devastating consequences of continued
embolization.References
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Circulation. 1999;100(Suppl):II54-62.Subcostal to rib-cross incision for HeartMate II explantation: A case
reportTakashi Nishimura, MD, Takeyoshi Ota, MD, PhD, Hiroo Takayama, MD, PhD, and
Yoshifumi Naka, MD, PhD, New York, NYThe role of left ventricular assist devices (LVADs) is ex-
pected to become more important because of an increasing
number of patients experiencing heart failure and a shortage
heart transplant donors.1 LVAD explantation following
myocardial recovery is well documented2 and most of the
patients requiring the procedure have multiple medical
problems, making minimally invasive methods more attrac-
tive. Several surgical approaches have been reported.3,4 We
report 2 cases of LVAD explantation using a subcostal to
rib-cross incision combined with a separate anteriolateral
minithoracotomy.CLINICAL SUMMARY
The first patient was 57 years old and had a HeartMate II
(Thoratec, Pleasanton, Calif) LVAD implant for cardiogenic
shock after redo aortic valve replacement. The patient’s
ejection fraction (EF) improved from 15% to 45% over 2
months and the LVAD was explanted 64 days after LVAD
implantation. The second patient was 47 years old and
had an HeartMate II LVAD implant for cardiogenic shock
after coronary artery bypass grafting and mitral valve repair.
The EF in this patient improved from 10% to 60% over 5
months and the LVAD was explanted 149 days after it had
been implanted.
A subcostal incision was made over the device and ex-
tended laterally toward the rib cage to match placement ofthe device. The apex of the heart and the device inflow
was exposed by excising the seventh rib. The upper side
of the costal incision was retracted for exposure (Figure 1,
A). Simultaneously, a small right thoracotomy through the
third intercostal space was performed and the outflow graft
was exposed (Figure 1, B). Cardiopulmonary bypass (CPB)
was established from the right femoral artery (BioMedicus
17Fr cannula, Medtronic, Minneapolis, Minn) and vein
(Biomedicus 21Fr cannula, Medtronic) (Figure 2). The
left ventricular vent was not placed. The LVAD flow was
discontinued and the outflow graft was clamped as soon
as CPB was started. While in Trendelenburg position, the
apical inflow cannula was removed. A left ventricular
plug made from rolled felt was inserted into the left ventric-
ular apical cuff and secured using no. 5 TiCron sutures
(Covidien, Mansfield, Mass) and reinforced with Bioglue
(CryoLife, Kennesaw, Ga) on its end. The outflow graft,
which had been clamped since CPB started, was used as
a root vent to deair by periodically opening the clamp.
The CPB was weaned and came off followed by protamine
reverse (CPB time 17 minutes and 49 minutes, respec-
tively). The outflow graft was stapled and transected using
a white vascular EndoGIA (Covidien) through the minithor-
acotomy. The bend relief was removed through the subcos-
tal incision. Blake silicone drains (19Fr; Ethicon,
Somerville, NJ) were placed in right pleural space, the out-
flow graft tunnel, and the device pocket. The incisions were
closed in the standard fashion. Postoperative bleeding was
minimal and the postoperative course was uneventful for
both patients.DISCUSSION
There are about 5 million patients with heart failure in the
United States. Heart transplantation has been limited by the
number of donors and has reached a plateau at about 4500ery c January 2013
